Literature DB >> 30568106

Evaluation of in Vitro Bactericidal Activity of 1.5% Olanexidine Gluconate, a Novel Biguanide Antiseptic Agent.

Shoji Seyama1, Hisae Nishioka2, Hidemasa Nakaminami1, Keisuke Nakase1, Takeaki Wajima1, Akifumi Hagi2, Norihisa Noguchi1.   

Abstract

Recently, 1.5% olanexidine gluconate, a biguanide compounds, was launched as a new antiseptic agent in Japan. However, the comprehensive bactericidal spectrum of olanexidine gluconate is still unknown. In this study, we evaluated in vitro bactericidal activity of olanexidine gluconate using time-kill assay against various bacteria, mycobacteria, and fungi. With the exception of Burkholderia cepacia and Mycobacterium spp., 1.5% olanexidine gluconate exhibited fast-acting (≤60 s) bactericidal activity against all tested Gram-positive and Gram-negative bacteria, including vancomycin-resistant Enterococcus faecalis, methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis, extended spectrum β-lactamase producing Klebsiella pneumoniae, and multidrug-resistant Pseudomonas aeruginosa. Furthermore, 1.5% olanexidine gluconate eradicated Candida albicans, Microsporum canis, and Malassezia furfur within 3 min. Our findings indicate that olanexidine gluconate has broad spectrum bactericidal activity; therefore, it may be useful for the prevention of a wide range of infectious diseases.

Entities:  

Keywords:  bactericidal spectrum; disinfectant; olanexidine gluconate; time-kill assay

Mesh:

Substances:

Year:  2018        PMID: 30568106     DOI: 10.1248/bpb.b18-00821

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  3 in total

Review 1.  Clinical application of skin antisepsis using aqueous olanexidine: a scoping review.

Authors:  Yutaro Shinzato; Eiryu Sakihara; Yuki Kishihara; Masahiro Kashiura; Hideto Yasuda; Takashi Moriya
Journal:  Acute Med Surg       Date:  2022-01-07

2.  Clinical study of a new skin antiseptic olanexidine gluconate in gastrointestinal cancer surgery.

Authors:  Naoki Kubo; Norihiko Furusawa; Daisuke Takeuchi; Shinichiro Imai; Hitoshi Masuo; Kentaro Umemura; Masaru Terada
Journal:  BMC Surg       Date:  2022-05-19       Impact factor: 2.102

3.  In vitro growth-inhibitory effects of Portulaca oleracea L. formulation on intestinal pathogens.

Authors:  Sae Okuda; Takeaki Wajima; Tetsuya Yamada; Hidemasa Nakaminami; Hideaki Ikoshi; Norihisa Noguchi
Journal:  Access Microbiol       Date:  2021-02-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.